Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, especially for those who opt to reinvest the dividend.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a maintenance fee in 2019.

These findings suggest that CagriSema could represent a highly effective therapeutic option for both weight and glycaemic management in people with Type 2 diabetes. While the gastrointestinal side ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

As the weight loss treatment space reaches a new saturation point, Novo Nordisk, Eli Lilly and their closest—but still distant—competitors continue to vie for a greater share of the ever- expanding ...

Still, experts say CagriSema could become a powerful new tool in the global effort to address obesity. At UAB, Garvey holds the C. E. Butterworth, Jr., MD, Professorship in the Department of Nutrition ...